Skip to main content
Erschienen in: Digestive Diseases and Sciences 5/2015

01.05.2015 | Original Article

IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2–ERK1/2 Pathway

verfasst von: Xi-Xiang Yu, Zhe Hu, Xian Shen, Li-Yang Dong, Wei-Zhong Zhou, Wen-Hao Hu

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

As a pro-inflammatory cytokine, IL-33 has been demonstrated to play an important role in tumor progression. It is reported that IL-33 is highly expressed in the serum and tumor tissues of patients with gastric cancer. However, the function of IL-33 in gastric cancer remains elusive. We here tried to elucidate the effects of IL-33 on gastric cancer cell invasion and migration.

Methods

Invasion assay and migration assay were performed to assess the effects of IL-33 on gastric cancer cell invasion and migration. ST2 receptor was silenced by siRNA, and ERK1/2 pathway was inhibited by U0126. Protein levels of MMP-3 and IL-6 in cell supernatant were measured by ELISA.

Results

IL-33 promoted the invasion and migration of gastric cancer cells, in a dose-dependent manner. Knockdown of the IL-33 receptor ST2 attenuated the IL-33-mediated invasion and migration. Furthermore, via ST2 receptor, IL-33 induced the activation of ERK1/2 and increased the secretion of MMP-3 and IL-6. In addition, blockage of ERK1/2 pathway resulted in inhibition of invasion and migration induced by IL-33, and downregulation of MMP-3 and IL-6 production.

Conclusions

IL-33 promotes gastric cancer cell invasion and migration by stimulating the secretion of MMP-3 and IL-6 via ST2–ERK1/2 pathway. Thus, IL-33 may be a useful marker for the diagnosis and treatment of gastric cancer.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Zurück zum Zitat Viudez-Berral A, Miranda-Murua C, Arias-de-la-Vega F, et al. Current management of gastric cancer. Rev Esp Enferm Dig. 2012;104:134–141.CrossRefPubMed Viudez-Berral A, Miranda-Murua C, Arias-de-la-Vega F, et al. Current management of gastric cancer. Rev Esp Enferm Dig. 2012;104:134–141.CrossRefPubMed
3.
Zurück zum Zitat Ikeguchi M, Hatada T, Yamamoto M, et al. Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer. 2009;12:95–100.CrossRefPubMed Ikeguchi M, Hatada T, Yamamoto M, et al. Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer. 2009;12:95–100.CrossRefPubMed
4.
Zurück zum Zitat Onda H, Kasuya H, Takakura K, et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 1999;19:1279–1288.CrossRefPubMed Onda H, Kasuya H, Takakura K, et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 1999;19:1279–1288.CrossRefPubMed
5.
Zurück zum Zitat Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–490.CrossRefPubMed Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–490.CrossRefPubMed
6.
Zurück zum Zitat Tominaga S, Jenkins NA, Gilbert DJ, Copeland NG, Tetsuka T. Molecular cloning of the murine ST2 gene. Characterization and chromosomal mapping. Biochim Biophys Acta. 1991;1090:1–8.CrossRefPubMed Tominaga S, Jenkins NA, Gilbert DJ, Copeland NG, Tetsuka T. Molecular cloning of the murine ST2 gene. Characterization and chromosomal mapping. Biochim Biophys Acta. 1991;1090:1–8.CrossRefPubMed
7.
Zurück zum Zitat Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J. 1994;13:1176–1188.PubMedCentralPubMed Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J. 1994;13:1176–1188.PubMedCentralPubMed
8.
Zurück zum Zitat Liu J, Shen JX, Hu JL, Huang WH, Zhang GJ. Significance of interleukin-33 and its related cytokines in patients with breast cancers. Front Immunol. 2014;5:141.CrossRefPubMedCentralPubMed Liu J, Shen JX, Hu JL, Huang WH, Zhang GJ. Significance of interleukin-33 and its related cytokines in patients with breast cancers. Front Immunol. 2014;5:141.CrossRefPubMedCentralPubMed
9.
Zurück zum Zitat Hu LA, Fu Y, Zhang DN, Zhang J. Serum IL-33 as a diagnostic and prognostic marker in non-small cell lung cancer. Asian Pac J Cancer Prev. 2013;14:2563–2566.CrossRefPubMed Hu LA, Fu Y, Zhang DN, Zhang J. Serum IL-33 as a diagnostic and prognostic marker in non-small cell lung cancer. Asian Pac J Cancer Prev. 2013;14:2563–2566.CrossRefPubMed
10.
Zurück zum Zitat Musolino C, Allegra A, Profita M, et al. Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease. Br J Haematol. 2013;160:709–710.CrossRefPubMed Musolino C, Allegra A, Profita M, et al. Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease. Br J Haematol. 2013;160:709–710.CrossRefPubMed
11.
Zurück zum Zitat Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci. 2011;56:3596–3601.CrossRefPubMed Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci. 2011;56:3596–3601.CrossRefPubMed
12.
Zurück zum Zitat Kunisch E, Chakilam S, Gandesiri M, Kinne RW. IL-33 regulates TNF-alpha dependent effects in synovial fibroblasts. Int J Mol Med. 2012;29:530–540.PubMedCentralPubMed Kunisch E, Chakilam S, Gandesiri M, Kinne RW. IL-33 regulates TNF-alpha dependent effects in synovial fibroblasts. Int J Mol Med. 2012;29:530–540.PubMedCentralPubMed
13.
Zurück zum Zitat Mine Y, Makihira S, Yamaguchi Y, Tanaka H, Nikawa H. Involvement of ERK and p38 MAPK pathways on interleukin-33-induced RANKL expression in osteoblastic cells. Cell Biol Int. 2014;38:655–662.CrossRefPubMed Mine Y, Makihira S, Yamaguchi Y, Tanaka H, Nikawa H. Involvement of ERK and p38 MAPK pathways on interleukin-33-induced RANKL expression in osteoblastic cells. Cell Biol Int. 2014;38:655–662.CrossRefPubMed
14.
Zurück zum Zitat Chen XJ, Huang YD, Li N, et al. Correlations between serum IL33 and tumor development: a meta-analysis. Asian Pac J Cancer Prev. 2014;15:3503–3505.CrossRefPubMed Chen XJ, Huang YD, Li N, et al. Correlations between serum IL33 and tumor development: a meta-analysis. Asian Pac J Cancer Prev. 2014;15:3503–3505.CrossRefPubMed
15.
Zurück zum Zitat Xie Q, Wang SC. IL-33, an important biomarker in non-small-cell lung cancer? Asian Pac J Cancer Prev. 2013;14:7763.CrossRefPubMed Xie Q, Wang SC. IL-33, an important biomarker in non-small-cell lung cancer? Asian Pac J Cancer Prev. 2013;14:7763.CrossRefPubMed
16.
Zurück zum Zitat Santulli P, Even M, Chouzenoux S, et al. Profibrotic interleukin-33 is correlated with uterine leiomyoma tumour burden. Hum Reprod. 2013;28:2126–2133.CrossRefPubMed Santulli P, Even M, Chouzenoux S, et al. Profibrotic interleukin-33 is correlated with uterine leiomyoma tumour burden. Hum Reprod. 2013;28:2126–2133.CrossRefPubMed
17.
Zurück zum Zitat Zhang P, Liu XK, Chu Z, et al. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res. 2012;40:1654–1661.CrossRefPubMed Zhang P, Liu XK, Chu Z, et al. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res. 2012;40:1654–1661.CrossRefPubMed
18.
Zurück zum Zitat Chen SF, Nieh S, Jao SW, et al. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol. 2013;231:180–189.CrossRefPubMed Chen SF, Nieh S, Jao SW, et al. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol. 2013;231:180–189.CrossRefPubMed
19.
Zurück zum Zitat Bergis D, Kassis V, Ranglack A, et al. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol. 2013;6:311–318.CrossRefPubMedCentralPubMed Bergis D, Kassis V, Ranglack A, et al. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol. 2013;6:311–318.CrossRefPubMedCentralPubMed
21.
Zurück zum Zitat Jovanovic IP, Pejnovic NN, Radosavljevic GD, et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer. 2014;134:1669–1682.CrossRefPubMed Jovanovic IP, Pejnovic NN, Radosavljevic GD, et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer. 2014;134:1669–1682.CrossRefPubMed
22.
Zurück zum Zitat Jovanovic IP, Pejnovic NN, Radosavljevic GD, Arsenijevic NN, Lukic ML. IL-33/ST2 axis in innate and acquired immunity to tumors. Oncoimmunology. 2012;1:229–231.CrossRefPubMedCentralPubMed Jovanovic IP, Pejnovic NN, Radosavljevic GD, Arsenijevic NN, Lukic ML. IL-33/ST2 axis in innate and acquired immunity to tumors. Oncoimmunology. 2012;1:229–231.CrossRefPubMedCentralPubMed
23.
Zurück zum Zitat Yagami A, Orihara K, Morita H, et al. IL-33 mediates inflammatory responses in human lung tissue cells. J Immunol.. 2010;185:5743–5750.CrossRefPubMed Yagami A, Orihara K, Morita H, et al. IL-33 mediates inflammatory responses in human lung tissue cells. J Immunol.. 2010;185:5743–5750.CrossRefPubMed
24.
Zurück zum Zitat Tanabe T, Shimokawaji T, Kanoh S, Rubin BK. IL-33 stimulates CXCL8/IL-8 secretion in goblet cells but not normally differentiated airway cells. Clin Exp Allergy. 2014;44:540–552.CrossRefPubMedCentralPubMed Tanabe T, Shimokawaji T, Kanoh S, Rubin BK. IL-33 stimulates CXCL8/IL-8 secretion in goblet cells but not normally differentiated airway cells. Clin Exp Allergy. 2014;44:540–552.CrossRefPubMedCentralPubMed
25.
Zurück zum Zitat Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279–3290.CrossRefPubMed Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279–3290.CrossRefPubMed
26.
Zurück zum Zitat Luzina IG, Pickering EM, Kopach P, et al. Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. J Immunol. 2012;189:403–410.CrossRefPubMedCentralPubMed Luzina IG, Pickering EM, Kopach P, et al. Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. J Immunol. 2012;189:403–410.CrossRefPubMedCentralPubMed
27.
Zurück zum Zitat Zhao J, Zhang H, Liu SB, et al. Spinal interleukin-33 and its receptor ST2 contribute to bone cancer-induced pain in mice. Neuroscience. 2013;253:172–182.CrossRefPubMed Zhao J, Zhang H, Liu SB, et al. Spinal interleukin-33 and its receptor ST2 contribute to bone cancer-induced pain in mice. Neuroscience. 2013;253:172–182.CrossRefPubMed
Metadaten
Titel
IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2–ERK1/2 Pathway
verfasst von
Xi-Xiang Yu
Zhe Hu
Xian Shen
Li-Yang Dong
Wei-Zhong Zhou
Wen-Hao Hu
Publikationsdatum
01.05.2015
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2015
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3463-1

Weitere Artikel der Ausgabe 5/2015

Digestive Diseases and Sciences 5/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.